Trump is reportedly battling Big Pharma on drug pricing — but someone inside his administration may be working to raise prescription costs ahead of the midterms.

The contradiction raises questions about internal policy conflicts and whether industry-friendly officials are undermining the president's public stance on lowering drug prices for voters.